Widespread drug prescription and abuse have necessitated the monitoring of patients for compliance. Often, patient samples are first screened by immunoassay to identify the presence of drugs, and then identification and quantity is confirmed by mass spectrometry (MS). A way to decrease costs while increasing sample accuracy and number of analytes during screening has been achieved by utilizing high resolution mass spectrometry (HRMS), in particular the Q-Exactive™.
In this study, a method was developed in which 47 drugs in urine were simultaneously screened and quantified by liquid chromatography (LC)-HRMS utilizing data independent acquisition (DIA). IMCSzyme®, a genetically modified β-glucuronidase, was selected for this application because of its non-selective hydrolysis capabilities over a wide range of drugs as well as its efficient and high rate of hydrolysis, reducing the likelihood of obtaining false negatives. In addition, IMCSzyme® is in the form of a pure solution, which reduces the contaminants loaded onto the system.
Summary by IMCS from the technical poster “Screening and Quantification of Pain and Antidepressant Drugs in Human Urine by Liquid Chromatography-High Resolution Mass Spectrometry” presented by Ana Celia Grenier, Ph.D - Dominion Diagnostics at ASMS 2016